ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2541

Autoantibodies in Pediatric Sjogren’s Patients

Lakshmanan Suresh1, Minako Tomiita2, Akira Hoshioka3, Long Shen4, Kishore Malyavantham5 and Julian Ambrus6, 160 Pineview Drive, State University of New York/Buffalo, Buffalo, NY, 2Department of Allergy and Rheumatology, Chiba Children’s Hospital, Chiba, Japan, 3Department of Allergy and Rheumatology,, Chiba Children’s Hospital,, Chiba, Japan, 4Department of Medicine, SUNY at Buffalo, Buffalo, NY, 5Research and Development, IMMCO Diagnostics Inc ., Amherst, NY, 6100 High St., University Of Buffalo, Buffalo, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: antibodies and pediatrics, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Sjogren's Syndrome: Clinical Science

Session Type: Abstract Submissions (ACR)

Background/Purpose

Sjogren’s syndrome (SS) is a common autoimmune disease involving the salivary and lacrimal glands along with various other organs. It is generally seen in adult females and it is considered ‘rare’ in children. However, there are not a few pediatric SS patients, and their clinical features are different from those of adults. It is because pediatric patients are in early stages of the disease. The current studies were designed to characterize SS in a population of pediatric patients and whether anti-SP1, anti-CA6 and anti-PSP antibodies could be a new disease marker of early stages of SS.

Methods

Sera were obtained from 15 patients, 4 fulfilled the revised Japanese diagnostic criteria for SS and 11 who probably have SS from the Department of Allergy and Rheumatology, Chiba Children’s Hospital, Chiba City, Japan.  Their age range was 3-18 years with a mean age of 10.98 years. Fifty pediatric normal controls who were age and sex matched were obtained from Promedx Corporation, USA.  ANA was evaluated by HEp2-IFA (Immunofluorescence), RF (Rheumatoid Factor), anti-Ro, anti-La, anti-SP1, anti-CA6 and anti-PSP by ELISA as previously described.

Results

Of the 15 pediatric patients, 11 were females (73%), 2 had SS secondary to SLE and 1 had MCTD. The majority of the patients (80%) expressed ANA and 40% RF. Anti-Ro was expressed by 7 patients of whom 2 also expressed anti-La and 1 also expressed anti-SP1 whose sialography was negative. One 6 year-old patient expressed anti-CA6 and anti-PSP without anti-Ro or anti-La.  Of the 50 pediatric normal controls, ANA, anti-Ro, anti-La, anti-CA6 were all negative. Four normal controls expressed RF, 1 had a low titer for anti-PSP and one a low titer for anti-SP1.

Conclusion

Pediatric patients with SS are frequently ANA and anti-Ro positive. One patient lacking these autoantibodies expressed anti-CA6 and anti-PSP and one patient whose sialography was negative expressed anti-SP1. These antibodies may be new disease markers of SS in early stages. In general, a larger percentage of pediatric Sjogren’s patients compared to adult patients were male.

The pattern of autoantibody expression in pediatric Sjogren’s patients was different from what has been historically seen in adult Sjogren’s patents. Further studies will be necessary to look at a larger population of pediatric Sjogren’s patients over time to evaluate the progression of their disease and the pattern of their autoantibody expression.


Disclosure:

L. Suresh,
None;

M. Tomiita,
None;

A. Hoshioka,
None;

L. Shen,
None;

K. Malyavantham,
None;

J. Ambrus,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoantibodies-in-pediatric-sjogrens-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology